drugset / Trial / NCT01280305

Raloxifene in Treatment of Schizophrenia and Schizoaffective Disorder

NCT01280305

Phase 3 Unknown 200 enrolled Sheba Medical Center
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The objective of the study is to evaluate the efficacy of raloxifene compared to placebo, as add-on to anti-psychotics in the treatment of post menopausal patients with schizophrenia.

Timeline

Start
2011-03
Primary completion
2012-12
Completion
2013-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Raloxifene Other / unclassified 60 mg